Login / Signup
Everyone knows that cannibalism was practiced widely in pre-Colombian Mexico. Go online and you will quickly learn that 15,000 to 20,000 Aztecs were sacrificed each…
Outsiders Swoop In Vowing To Rescue Rural Hospitals Short On Hope — And Money
Editor’s note: the following article is reprinted with permission from Kaiser Health News. Links to previous CardioBrief coverage of the laboratory scandal story can be…
New ORBITA Findings May Offer Modest Symptomatic Pain Relief To Interventional Cardiologists
New data presented at EuroPCR from the much debated ORBITA trial may provide some modest temporary lessening of the pain felt by interventional cardiologists in…
NIH Halts Large Cardiovascular Inflammation Reduction (CIRT) Trial
The NHLBI has put an early stop to the large Cardiovascular Inflammation Reduction (CIRT) Trial. The NHLBI action was based on a recommendation from the trial’s…
Salt War Opponents Unite In Call For Randomized Trial In Prisons
The opposing camps in the salt wars don’t agree on much, but they have now found common ground in their belief that the only way…
American Heart Association Venture Capital Fund Sparks Criticism
(Updated) The American Heart Association has announced that it has launched a $30 million venture capital fund “designed to spur healthcare innovation in heart disease and stroke…
CABANA: No Outcomes Benefit In First Big Trial Of AF Ablation
(Updated) Catheter ablation for atrial fibrillation (AF) produced no significant improvement in clinical outcomes in a large and important new clinical trial. CABANA is the…
More Controversy Over Major Cardiology Clinical Trial
Think about this: A new article reports that a major NIH-funded trial runs into trouble. The article raises all sorts of fundamental questions about our…
Cardiology World Erupts Into Controversy Over Change In Major Clinical Trial
As a major clinical trial in cardiology nears completion it has provoked a storm of criticism and controversy. The brouhaha erupted in response to a…
The ODYSSEY Trial Ends Well— But Will It Be Enough?
Sanofi and Regeneron achieved a modest victory with the much anticipated ODYSSEY Outcomes trial of its cholesterol lowering drug Praluent (alirocumab). The trial met its…